Provided by Tiger Trade Technology Pte. Ltd.

Quantum Biopharma Ltd.

2.94
-0.1700-5.47%
Post-market: 2.980.0400+1.36%19:42 EDT
Volume:129.97K
Turnover:393.88K
Market Cap:23.78M
PE:-0.55
High:3.11
Open:3.11
Low:2.94
Close:3.11
52wk High:16.36
52wk Low:2.07
Shares:8.09M
Float Shares:7.65M
Volume Ratio:0.55
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.3537
EPS(LYR):-7.9660
ROE:-621.46%
ROA:-51.84%
PB:2.99
PE(LYR):-0.37

Loading ...

US Judge Consolidates Quantum BioPharma Stock-Manipulation Suits Against CIBC, RBC

Reuters
·
Oct 08

World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

GlobeNewswire
·
Oct 08

Quantum BioPharma (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial

TIPRANKS
·
Oct 08

Quantum BioPharma (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial

TIPRANKS
·
Oct 07

Quantum BioPharma signs contract with Thermo Fisher for sclerosis trial

TIPRANKS
·
Oct 06

Quantum BioPharma Signs Thermo Fisher Clinical Research Unit Contract to Launch Phase 2 MS Trial

Reuters
·
Oct 06

Quantum Biopharma - Thermo Fisher to Support Phase 2 Lucid-MS Clinical Trial Implementation

THOMSON REUTERS
·
Oct 06

Quantum BioPharma (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing

TIPRANKS
·
Sep 25

Quantum BioPharma Licensee Unbuzzd Names Michael Zapolin CEO

Reuters
·
Sep 24

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

GlobeNewswire
·
Sep 24

Quantum BioPharma (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

TIPRANKS
·
Sep 24

Inside Quantum World Congress: Where FBI Agents, Big Tech, and Stock Hype Converge

Dow Jones
·
Sep 24

Quantum BioPharma Board Authorizes Class a Multiple-Voting Share Offering to Lift Control Stake to 75.27%

Reuters
·
Sep 18

Quantum BioPharma Plans Debt Conversion at Conversion Price of CAD 4 Per Share

Reuters
·
Sep 18

Quantum BioPharma Grants 7,692 Stock Options to Director Zapolin at C$ 6.6 Per Share

Reuters
·
Sep 18

Quantum BioPharma (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target

TIPRANKS
·
Sep 18

Rodman & Renshaw Initiates Quantum BioPharma Coverage with Buy Rating, US$ 8 Target

Reuters
·
Sep 17

Quantum BioPharma (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit

TIPRANKS
·
Sep 16

Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto

GlobeNewswire
·
Sep 15

Stray Alert on Quantum BioPharma Withdrawn

Reuters
·
Sep 14